| DIRECT COMPETITOR COMPARISON | |
| AUXL | PRX | SVYSY.PK | WPI | Industry | | Market Cap: | 1.65B | 845.06M | N/A | 4.01B | 83.82M | | Employees: | 340 | 654 | N/A | 5,070 | 280 | | Qtrly Rev Growth (yoy): | 29.30% | 97.90% | N/A | 3.30% | 9.60% | | Revenue (ttm): | 150.79M | 1.06B | N/A | 2.65B | 71.35M | | Gross Margin (ttm): | 76.84% | 28.00% | N/A | 44.90% | 49.96% | | EBITDA (ttm): | -49.99M | 140.74M | N/A | 642.17M | 214.30K | | Oper Margins (ttm): | -35.53% | 9.73% | N/A | 17.41% | 7.24% | | Net Income (ttm): | -53.70M | 39.79M | N/A | 221.48M | N/A | | EPS (ttm): | -1.267 | 1.117 | N/A | 1.940 | N/A | | P/E (ttm): | N/A | 21.73 | N/A | 19.49 | 18.14 | | PEG (5 yr expected): | N/A | 0.18 | 2.65 | 1.19 | 0.96 | | P/S (ttm): | 11.04 | 0.79 | N/A | 1.48 | 1.16 |
|
| PRX = Par Pharmaceutical Companies Inc. | | SVYSY.PK = | | WPI = Watson Pharmaceuticals Inc. | | Industry = Drug Related Products | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.08 | 0.49% | 57.77B | 12.45 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.45 | 0.15% | 13.72B | 15.88 | | Genzyme Corp. | GENZ | 51.52 | 2.26% | 13.67B | 29.37 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.98 | 0.04% | 42.28B | 18.17 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.89 | 1.41% | 9.08B | 1038.57 | | Teva Pharmaceutical Industries Limited | TEVA | 53.16 | -0.21% | 46.83B | 48.64 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.81 | 2.05% | 4.01B | 19.49 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 12.08 | 0.00% | 3.00B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.29 | -0.05% | 5.59B | 112.21 | | Pfizer Inc. | PFE | 18.59 | 1.53% | 150.01B | 15.44 | | Johnson & Johnson | JNJ | 63.30 | 0.19% | 174.65B | 13.82 | | GlaxoSmithKline plc | GSK | 42.88 | 1.42% | 108.70B | 13.48 | | Sanofi-Aventis | SNY | 39.46 | 2.15% | 103.03B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.85 | 0.99% | 126.85B | 16.72 | | RHHBY.PK | 42.29 | 2.03% | N/A | N/A | | AstraZeneca plc | AZN | 46.38 | 2.50% | 67.25B | 9.31 | | Abbott Laboratories | ABT | 54.41 | 0.31% | 84.16B | 14.74 | | Bristol-Myers Squibb Co. | BMY | 25.65 | 1.95% | 50.81B | 13.27 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | PRX | | Build Your Fortune With These Winners
Wed 3:00pm -
at Motley Fool | | • | PRX | | Par Pharma buys back $30.8M in senior notes
Wed 12:31pm -
AP | | • | PRX | | Par Pharmaceutical Announces Results of Its 'Modified Dutch Auction' Tender Offer
Wed 9:00am -
PR Newswire | | • | WPI | | Watson Pharmaceutical Financial Gauge Analysis for the September 2009 Quarter
Wed 5:16am -
at Seeking Alpha | | • | WPI | | Israel Stocks: Tel Aviv broadly higher; Israel Chemicals in focus
Mon, Nov 23 -
at MarketWatch | | • | PRX | | Drugmaker Par Shapes A Base But Needs Time
Fri, Nov 20 -
Investor's Business Daily | | • | WPI | | StockPreacher.com Issues Trading Outlook for Arena Pharmaceuticals Inc.
Wed, Nov 18 -
GlobeNewswire | | • | PRX | | Par Pharmaceutical to Host Analyst Day on December 3rd
Mon, Nov 16 -
PR Newswire | | • | WPI | | Watson Names Robert A. Stewart Senior Vice President, Global Operations
Mon, Nov 16 -
PR Newswire | | • | WPI | | WATSON PHARMACEUTICALS INC Financials
Fri, Nov 13 -
EDGAR Online Financials | | • | WPI | | Cephalon, Barr settle Fentora dispute
Thu, Nov 12 -
AP | | • | SVYSY.PK | | Abbott Buys Unit of Solvay for $7 Billion Cash
Mon, Sep 28 -
at SmartMoney.com | | • | SVYSY.PK | | Akzo Nobel In The Red
Thu, Apr 23 -
at Forbes.com | | | All Headlines for these symbols... |
|
|
|
0.29% Nasdaq 
0.36 (1.02%) 
Competitors
